Previous Article | Next Article ![]()
Antimicrobial Agents and Chemotherapy, March 2009, p. 1275-1277, Vol. 53, No. 3
0066-4804/09/$08.00+0 doi:10.1128/AAC.01244-08
Copyright © 2009, American Society for Microbiology. All Rights Reserved.

Department of Pathology, Hershey Medical Center, Hershey, Pennsylvania 17033
Received 18 September 2008/ Returned for modification 23 December 2008/ Accepted 26 December 2008
The in vitro postantibiotic effects (PAEs), postantibiotic sub-MIC effects (PA-SMEs), and sub-MIC effects of telavancin were determined for 16 gram-positive organisms. Telavancin staphylococcal, streptococcal, and enterococcal PAE ranges were 0.9 to 3.9 h, 0.4 to 6.7 h, and 0.3 to 2.2 h, respectively. The PA-SME ranges (0.4 times the MIC) for staphylococci, streptococci, and enterococci were 6.7 to >10.7 h, >10.7 to >11.0 h, and >10 to >10.8 h, respectively. The extended PAE of telavancin, together with its long elimination half-life in humans, supports once-daily dosing for this investigational drug.
Published ahead of print on 5 January 2009.
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»